Compile Data Set for Download or QSAR
Report error Found 295 Enz. Inhib. hit(s) with all data for entry = 2467
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367317(Methyl (6RS)-4-oxo-3-(phenylamino)-2-(pyridin-4-yl...)
Affinity DataIC50: 3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367598(US10227299, Example 288)
Affinity DataIC50: 3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367367(US10227299, Example 61 | N-Methyl-4-oxo-3-(phenyla...)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367368(US10227299, Example 60 | N,N-Dimethyl-4-oxo-3-(phe...)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367372((6RS)-6-[(Ethylsulfanyl)methyl]-3-(phenylamino)-2-...)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367593(US10227299, Example 283)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367349((6RS)-6-Ethenyl-3-(phenylamino)-2-(pyridin-4-yl)-1...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367371((6RS)-3-(Phenylamino)-6-[(propan-2-ylsulfanyl)meth...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367412((6RS)—N-Methyl-N-(2-methylpropyl)-4-oxo-3-(ph...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367472(Methyl (6RS)-2-[3-(2-methoxyethoxy)pyridin-4-yl]-4...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367507((6RS)-2-2-[(4-Fluorobenzoyl)amino]pyridin-4-yl-N,N...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367590(US10227299, Example 280)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367592(US10227299, Example 282)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367391((6RS)-6-[(Ethylsulfonyl)methyl]-3-(phenylamino)-2-...)
Affinity DataIC50: 6nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367454(Methyl (6RS)-2-2-[(4-fluorobenzoyl)amino]pyridin-4...)
Affinity DataIC50: 6nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367334((6RS)—N,N-Dimethyl-4-oxo-3-(phenylamino)-2-(p...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367357(N-[(6RS)-4-Oxo-3-(phenylamino)-2-(pyridin-4-yl)-4,...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367384(N-(2-Hydroxyethyl)-N-methyl-4-oxo-3-(phenylamino)-...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367386((6RS)-2-(3-Fluoropyridin-4-yl)-N,N-dimethyl-4-oxo-...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367432((6RS)—N,N-Diethyl-4-oxo-3-(phenylamino)-2-(py...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367455(Methyl (6RS)-4-oxo-3-(phenylamino)-2-2-[(1,3-thiaz...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367463(N-4-[(6RS)-6-(Azidomethyl)-4-oxo-3-(phenylamino)-4...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367469(Methyl (6RS)-3-anilino-2-[3-(cyclopropylmethoxy)py...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367509((6RS)—N,N-Dimethyl-4-oxo-3-(phenylamino)-2-2-...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367515(US10227299, Example 203 | (6RS)-3-Anilino-N,N-dlis...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367595(US10227299, Example 285)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367597(US10227299, Example 287)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367327((6RS)—N-Ethyl-N-methyl-4-oxo-3-(phenylamino)-...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367339((6RS)-6-(Hydroxymethyl)-6-methyl-3-(phenylamino)-2...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367346((6RS)-6-(Aminomethyl)-3-(phenylamino)-2-(pyridin-4...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367360((4E/Z)-5-[(6RS)-Oxo-3-(phenylamino)-2-(pyridin-4-y...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367388((6RS)-2-(3-Fluoropyridin-4-yl)-N-(2-hydroxyethyl)-...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367474((6RS)-2-[3-(2-Methoxyethoxy)pyridin-4-yl]-N,N-dime...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367501(N-4-[(6RS)-6-[(Ethylsulfanyl)methyl]-4-oxo-3-(phen...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367502(N-(4-(6RS)-Oxo-3-(phenylamino)-6-[(propan-2-ylsulf...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367508((6RS)-2-2-[(4-Fluorobenzoyl)amino]pyridin-4-yl-N-(...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367541(US10227299, Example 229 | N-4-[(6RS)-6-[(2-Methoxy...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367543(US10227299, Example 231 | N-(4-(6RS)-Oxo-3-(phenyl...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367551(US10227299, Example 239 | N-4-[(6RS)-6-[(Ethylsulf...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367326((6RS)—N-(2-Hydroxyethyl)-N-methyl-4-oxo-3-(ph...)
Affinity DataIC50: 9nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367342((6RS)-6-(Azidomethyl)-3-(phenylamino)-2-(pyridin-4...)
Affinity DataIC50: 9nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367359(Methyl (6RS)-2-[2-(acetylamino)pyridin-4-yl]-4-oxo...)
Affinity DataIC50: 9nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367468(N-4-[(6RS)-6-(Aminomethyl)-4-oxo-3-(phenylamino)-4...)
Affinity DataIC50: 9nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367574(US10227299, Example 262 | N-{4-[(6RS)-3-Anilino-6-...)
Affinity DataIC50: 9nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367594(US10227299, Example 284)
Affinity DataIC50: 9nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367317(Methyl (6RS)-4-oxo-3-(phenylamino)-2-(pyridin-4-yl...)
Affinity DataIC50: 10nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367319((6RS)—N-Methyl-4-oxo-3-(phenylamino)-2-(pyrid...)
Affinity DataIC50: 10nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367321((6RS)-4-Oxo-3-(phenylamino)-2-(pyridin-4-yl)-4,5,6...)
Affinity DataIC50: 10nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367323(Methyl (6RS)-2-(3-fluoropyridin-4-yl)-4-oxo-3-(phe...)
Affinity DataIC50: 10nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM367333((6RS)—N-Methyl-4-oxo-3-(phenylamino)-N-propyl...)
Affinity DataIC50: 10nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 295 total ) | Next | Last >>
Jump to: